Shire shares jump as drug approval vindicates $5.2 bln NPS purchase
LONDON, Jan 26 (Reuters) - Shire Plc (Xetra: S7E.DE - news) shares gained more than 3 percent on Monday following news U.S. regulators had approved NPS Pharmaceuticals Inc (NasdaqGS: NPSP - news) 's drug Natpara, validating Shire's decision to buy NPS for $5.2 billion.
Natpara is designed to treat hypoparathyroidism, a rare condition in which the body's parathyroid gland does not secrete enough parathyroid hormone.
(Reporting by Ben Hirschler; Editing by Mark Potter)